Source-grounded facts extracted from Biohaven Ltd.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Biohaven Ltd. shareholders approved Advisory vote on the compensation paid to the Company’s named executive officers. at the 2026-04-28 meeting.
“Proposal No. 3 : Advisory vote on the compensation paid to the Company’s named executive officers. Votes For Votes Against Abstained Non-binding vote on the compensation of the Company’s named executive officers 87,521,620 4,202,883 1,486,826 Broker Non-Votes: 32,137,064 Proposal No. 3 was approved.”
Biohaven Ltd. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. at the 2026-04-28 meeting.
“Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 123,723,636 214,123 1,410,634 Broker Non-Votes: 0 Proposal No. 2 was approved.”
Biohaven Ltd. shareholders approved Election of directors for a term expiring at the 2029 Annual Meeting of Shareholders. at the 2026-04-28 meeting.
“Proposal No. 1 : Election of directors for a term expiring at the 2029 Annual Meeting of Shareholders. Votes For Votes Against Abstained Proposal No. 1(a): Michael T. Heffernan 76,133,746 15,092,665 1,984,918 Proposal No. 1(b): Irina Antonijevic, M.D., Ph.D. 76,612,017 14,616,115 1,983,197 Proposal No. 1(c): Robert J. Hugin 76,597,707 14,626,151 1,987,471 Broker Non-Votes: 32,137,064 All nominees were elected.”
Biohaven Ltd. reported financial results for first quarter ended March 31, 2026.
“On May 4, 2026, Biohaven Ltd. (the " Registrant ") issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
Biohaven Ltd. reported financial results for first quarter ended March 31, 2024.
“Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a review of recent accomplishments and anticipated upcoming developments.”
Biohaven Ltd. reported financial results for the fourth quarter and full year ended December 31, 2023.
“Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.”
Biohaven Ltd. reported financial results for second quarter ended June 30, 2023.
“Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.”
Biohaven Ltd. reported financial results for the first quarter ended March 31, 2023.
“On May 12, 2023, Biohaven Ltd. (the “ Registrant ”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.”
Biohaven Ltd. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2023 at the 2023-05-02 meeting.
“Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2023.”
Biohaven Ltd. shareholders approved Election of Directors for a term expiring at the 2026 Annual Meeting of Shareholders at the 2023-05-02 meeting.
“Proposal No. 1 : Election of Directors for a term expiring at the 2026 Annual Meeting of Shareholders.”
Biohaven Ltd. reported financial results for fourth quarter and full year ended December 31, 2022.
“On March 23, 2023, Biohaven Ltd. (the " Registrant ") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.”
Biohaven Ltd. reported financial results for third quarter ended September 30, 2022.
“issued a press release announcing its financial results for the third quarter ended September 30, 2022”
Matthew Buten was appointed as Chief Financial Officer at Biohaven Ltd..
“On September 28, 2022, the Company appointed Matthew Buten as Chief Financial Officer.”
Kishan Mehta was appointed as Director at Biohaven Ltd..
“Designated as Class III directors, with initial terms expiring at the 2025 annual meeting of Biohaven shareholders: • Vladimir Coric • Kishan Mehta”
Vladimir Coric was appointed as Director at Biohaven Ltd..
“Designated as Class III directors, with initial terms expiring at the 2025 annual meeting of Biohaven shareholders: • Vladimir Coric • Kishan Mehta”
Julia Gregory was appointed as Director at Biohaven Ltd..
“Designated as Class II directors, with initial terms expiring at the 2024 annual meeting of Biohaven shareholders: • Gregory Bailey • John Childs • Julia Gregory”
John Childs was appointed as Director at Biohaven Ltd..
“Designated as Class II directors, with initial terms expiring at the 2024 annual meeting of Biohaven shareholders: • Gregory Bailey • John Childs”
Gregory Bailey was appointed as Director at Biohaven Ltd..
“Designated as Class II directors, with initial terms expiring at the 2024 annual meeting of Biohaven shareholders: • Gregory Bailey”
Robert Hugin was appointed as Director at Biohaven Ltd..
“Designated as Class I directors, with initial terms expiring at the 2023 annual meeting of Biohaven shareholders: • Irina Antonijevic • Michael T. Heffernan • Robert Hugin”
Michael T. Heffernan was appointed as Director at Biohaven Ltd..
“Designated as Class I directors, with initial terms expiring at the 2023 annual meeting of Biohaven shareholders: • Irina Antonijevic • Michael T. Heffernan”
Irina Antonijevic was appointed as Director at Biohaven Ltd..
“The following persons were appointed as directors of Biohaven on September 28, 2022: Designated as Class I directors, with initial terms expiring at the 2023 annual meeting of Biohaven shareholders: • Irina Antonijevic”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.